Status: Recruiting
A Study of LY4515100 in Participants With Pain Following Third Molar Removal
The purpose of this study is to evaluate the safety and efficacy of LY4515100 and see how a single oral dose compares with placebo in acute postsurgical pain after removing impacted third molars. For each participant, the study may last approximately 6 weeks and will include a stay in a Clinical Research Unit (CRU) after third molar removal.
Participants needed: 212
Trial details
Phase: Phase 2Age: 18-40Biological sex: AllType: InterventionalSponsor: Eli Lilly and CompanyUpdated: May 1, 2026Locations: 1
Eligibility criteria
Participant has a body mass index (BMI) between 18.5 and 35.0 kilograms per mete... [+1]
Prior dental surgery within 60 days before screening or history of other surgica... [+4]